Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age

Next Previous
Trial Profile

A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MT-8972 (Primary) ; Aluminium hydroxide
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 30 Jul 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
  • 12 Sep 2011 Results presented at the Fourth ESWI Influenza Conference, according to a Medicago media release.
  • 30 Jun 2011 Final phase II results have been reported in a Medicago media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top